Discovery is experimentation. Proving it to an examiner is the hard part.
Discovery, assay and formulation work, process development, preclinical studies, and qualifying clinical trials can all qualify. Grants, foreign sites, and a missing record are what reduce the claim.
Photo by Julia Koblitz on Unsplash
A new or improved compound, formulation, assay, or process is a business component. Discovery and development inherently involve resolving genuine scientific and technical uncertainty through a systematic process of experimentation - screening, formulating, running assays, and iterating on results - which is precisely what the credit rewards.
Every qualifying activity must pass the IRC §41 four-part test - permitted purpose, technological in nature (the biological and physical sciences), elimination of uncertainty, and a process of experimentation. Much of preclinical and bench science maps to this naturally.
Two facts shape every life-sciences claim. First, audit scrutiny is high, so substantiation must be contemporaneous and organized by business component. Second, the funded-research screen matters: grant- and contract-funded work may be excluded where you don’t bear the risk or retain rights. We screen both before anything is claimed.
General and illustrative; eligibility depends on your facts.
Not activity categories - situations. If any of these read like a program you actually ran, there is very likely a qualified business component underneath it.
Buffers, blocking agents, and two detection chemistries were screened before the window opened wide enough to call a hit.
Why it can qualify
Method uncertainty resolved by systematic screening - the plainest possible example of a process of experimentation.
Excipient systems and solubilization approaches were formulated and placed on stability until one held through the study period.
Why it can qualify
Formulation development against a requirement that could not be predicted from first principles.
Column chemistries and gradient profiles were developed and validated until the method resolved both species reproducibly.
Why it can qualify
Analytical method development relies on the physical sciences and starts from genuine uncertainty about the appropriate design.
Media, feed strategy, and bioreactor conditions were explored in a designed experiment across several runs.
Why it can qualify
Process development for a bioprocess business component. A DoE is a documented, systematic evaluation of alternatives.
Resins and buffer conditions were screened at small scale before the change was ever taken into the suite.
Why it can qualify
Purification process development - and the resins, media, and plasticware consumed in the screen are supply QREs.
Mixing, oxygen transfer, and shear were re-engineered and re-tested until the larger scale reproduced the small-scale result.
Why it can qualify
Scale-up uncertainty is real technical uncertainty, not a manufacturing formality - and the scaled process is its own business component.
In vitro work and a dose-ranging design were run specifically to resolve it, with the protocol amended once on the data.
Why it can qualify
Preclinical work resolving a scientific question about safety, efficacy, or mechanism. Clinical-stage activities are analyzed one at a time, on their facts.
Illustrative situations, not client work. Whether any of them qualifies for you depends on your facts, your funding agreements, and your evidence.
Life-sciences work clears the science easily and then turns on the record: notebook entries, protocol versions, assay qualification runs, the batch that failed and the reason it failed. Written at the time, that record is evidence. Reconstructed at filing time, it is an assertion.
We pull it alongside the funding agreements and the CRO statements of work, because grant terms, partner milestones, and the site where the work was actually performed decide these claims more often than the biology does.
Representative activities we see meet the four-part test across discovery, development, and process science.
What spending counts toward the credit - tailored to how research organizations actually spend.
| Expense category | What goes into the base |
|---|---|
| Scientist & technician wages§41(b)(2)(A)-(B) | Wages for scientists and technicians performing, supervising, or directly supporting qualified research. |
| Contract research / CRO (65%)§41(b)(3) | 65% of amounts paid to U.S. CROs, trial sites, and contract researchers for qualified research performed on your behalf, where you bear the cost even if the research fails. |
| Reagents & lab consumables§41(b)(2)(C) | Reagents, media, and lab consumables used up in qualified research - not depreciable instruments. |
| Cloud & compute§41(b)(2)(A)(iii) | Amounts paid to rent compute for modeling, simulation, and data analysis used in qualified research. |
A directional shape for a research organization, not a benchmark. Life sciences is the one industry where outsourced research can rival internal payroll - and where its geography quietly decides the number.
Research paid for by a grant or contract under which you don’t bear the financial risk or retain substantial rights is generally excluded. The funding terms and the rights-and-risk analysis are decisive.
In practice that means reading the award letter, the collaboration agreement, and the CRO master services agreement - including the IP and data-rights clauses and whether payment was contingent on the science working. A study that skips this step is an examination waiting to happen.
Rarely on the science. Almost always on funding, geography, or the absence of a contemporaneous record - which is why we screen all three before a dollar enters a base.
§41(d)(4)(H)
Non-dilutive funding is excellent for the company and difficult for the credit. Research is funded, and excluded, unless you both bear the financial risk of failure and retain substantial rights in the results. Milestone payments under a partnership are the subtle case: whether they were contingent on the science working is the whole question.
§41(d)(4)(F)
A European or Indian CRO’s work is excluded regardless of how the master services agreement is written, who supervises the protocol, or where the invoice is paid. This is the most common overstatement we see in life-sciences claims, because CRO spend is large and its geography is rarely tracked in the ledger.
§41(d)(4)(A)
Manufacturing support, release testing, and process monitoring for a marketed product sit after the start of commercial production for that business component. The saving nuance is the same as in manufacturing: a genuinely new process is its own business component, so post-approval process development is not automatically caught.
§41(d)(4)(D), (G)
Stability testing on commercial lots, release assays, and routine analytical runs are excluded as ordinary quality control and routine data collection. So are market research, health-economics studies, and other work grounded in the social sciences rather than the biological or physical ones.
§41(d)(4)(C)
Reproducing an existing business component from a physical examination or from published plans is excluded. Generic and biosimilar programs are therefore fact-specific rather than categorically in or out: the formulation, analytical, and process development can involve genuine experimentation, but that analysis has to be performed, not assumed.
§41(b)(2)(C)
LC-MS systems, incubators, bioreactors, and other depreciable lab equipment fall outside the supply definition. Reagents, media, antibodies, resins, and plasticware consumed in the research are precisely what it covers - which makes the lab-supply ledger worth reading line by line.
If the IRS does examine a claim, Ricerca prepares the audit response, the documentation, and the technical defense of its study, and works alongside your tax preparer - that is what Audit Protection means, and it is included with every R&D credit study.
Two federal credits can reach the same trial spend. They cannot both take the same dollar in the same year, so the split is a decision, not a default.
A trial run to resolve uncertainty about a new compound’s safety, efficacy, or dosing can be qualified research. Payments to U.S. CROs and trial sites enter the base at 65% under §41(b)(3), and only where you bear the cost whether or not the research succeeds. Sites outside the United States are excluded under §41(d)(4)(F), which matters for multinational trials, and studies on a product after it is approved need a closer look under the §41(d)(4)(A) exclusion for research after commercial production.
For a drug designated under section 526 of the Federal Food, Drug, and Cosmetic Act for a rare disease or condition, §45C allows a credit of 25% of qualified clinical testing expenses: human clinical testing under an FDA investigational exemption, carried out by or for the designation holder after the designation and before approval. It is claimed on Form 8820.
No double benefit. Expenses you elect to take into account under §45C are not counted toward the §41 credit for that year, though those that are also QREs still count in the §41 base for later years (§45C(c)). And §280C(b) reduces your deduction by the orphan credit unless you elect the reduced credit.
| Question | §41 research credit | §45C orphan drug credit |
|---|---|---|
| What it reaches | Qualified research across discovery, development, and clinical work | Human clinical testing of a drug designated for a rare disease or condition, after designation and before approval |
| Rate | ASC: 14% of QREs above 50% of the prior three-year average (6% if any of those three years had no QREs), or the regular 20% credit over a fixed base | 25% of qualified clinical testing expenses, or 19.75% with the §280C(b) reduced-credit election |
| Contract research | 65% of amounts paid, for research performed in the U.S. | 100% of amounts paid for clinical testing |
| Trial sites outside the U.S. | Excluded | Can count only where there is an insufficient U.S. testing population and the other statutory conditions are met |
| Grant-funded costs | Excluded to the extent funded | Excluded to the extent funded |
| Payroll tax offset | Available to a qualified small business, up to $500,000 a year | Not available |
| Form | Form 6765 | Form 8820 |
For a pre-revenue company the payroll offset can change the answer, because it is measured by the §41 credit only. We work through the choice in clinical trials: orphan drug credit vs. R&D credit.
A pre-revenue, clinical-stage biotech with a large research payroll is the exact profile §41(h) was written for. A qualified small business may elect to apply up to $500,000 of research credit per year against payroll taxes instead of income tax - the employer share of Social Security tax first, and the Medicare share above that - turning a credit you could not otherwise use into quarterly cash.
The definition is where otherwise-eligible companies fall out. It requires gross receipts under $5 million for the credit year and no gross receipts before the five-year window ending in that year, so an early collaboration payment or a small grant recorded as revenue six years ago can close the door. The election is made on a timely-filed return, claimed on Form 8974 with your quarterly employment tax return, and cannot be made for more than five tax years. The offset starts in the first calendar quarter beginning after that income tax return is filed, and it applies to the §41 credit only, not to the orphan drug credit.
Summary only - the statutory definition and the aggregation rules decide it. We test them explicitly.
Each state credit runs off its own base and rules, so start with the states where the research is actually performed. New Jersey deserves a specific look for biotech. Besides its corporate R&D credit, the NJEDA Technology Business Tax Certificate Transfer (NOL) Program lets qualifying unprofitable technology and biotechnology companies with fewer than 225 U.S. employees sell New Jersey net operating losses and unused R&D tax credits to unrelated profitable corporations for at least 80% of their value, up to a $20 million lifetime benefit per business.
The 2026 application cycle closed on June 30, 2026, and NJEDA expects to reopen applications in early May 2027. Eligibility also turns on New Jersey headcount, company age, and owning or licensing protected intellectual property, so check the program rules before planning around it.
Rates, caps, and refundability differ by state and change; each page shows the rules the platform computes from.
A hypothetical scenario to show how the pieces fit together. It is not a quote, projection, or promise of results.
On these facts the first question is not the size of the credit but whether the §41(h) election is available - up to $500,000 of it could come back as payroll-tax cash rather than a carryforward.
Illustrative only. Figures are hypothetical and rounded; CRO work is included at 65% and assumes no funded-research exclusion applies. The federal credit commonly works out to roughly 6-10% of QRE depending on method, filing history, and the §280C election. Your result depends entirely on your facts. This is not a quote or a promise of any result.
IRC §174A restores immediate, full expensing of domestic research & experimental costs for tax years beginning after December 31, 2024 - including qualified domestic discovery and development. Captured alongside the §41 credit, you get the deduction and the credit.
Tell us about your research and CRO work, and we’ll map your qualifying activities to the four-part test - screening for funded research and foreign performance, and capturing §174A - with contemporaneous, expert-finalized substantiation. Contact us for pricing tailored to your study.
We typically reply within one business day.
